CARsgen boasts of two cases of long-term HCC survival with CAR-T

China’s CARsgen Therapeutics (HK: 2171) has announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with its CAR-GPC3 T-cell therapy.

These cases date back to May 2015, when the Department of Interventional Oncology of Renji Hospital in Shanghai collaborated with CARsgen to begin the first clinical study with CAR T-cell therapy targeting the GPC3 (Glypican-3) protein in advanced HCC.

"Two patients with advanced HCC have achieved disease-free survival for more than seven years"At the time of enrollment, two patients already presented inferior vena cava tumor thrombus, and one of them also had retroperitoneal lymph node metastasis, a particularly poor prognosis factor for the outcome.